Diet and supplements for body, brain, and longevity in APOE e4 carriers
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether a special diet and supplements can improve body, brain, and longevity in people who carry the APOE e4 gene. It may help slow aging and support memory, but it requires a fairly restrictive health profile.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 45 and 65 years old.
- You must carry at least one copy of the APOE e4 gene variant (often linked to Alzheimer's risk).
- You must have a body mass index (BMI) between 20 and 39.
- You must be generally healthy, with no major medical conditions like diabetes, heart disease, or neurological disorders.
- You must have no food allergies and not be on a special diet (like keto or paleo) currently or in the past 3 months.
- You must be able to have an MRI (no metal implants, no severe claustrophobia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a digital lifestyle coaching program designed to help prevent Alzheimer's disease in people who carry the APOE4 genetic variant, which increases risk. Over one year, you'll get personalized health coaching through apps and possibly a smart ring to track your progress.
This study tests whether actively lowering blood pressure and cholesterol can slow down or prevent memory decline in people who carry a genetic risk for Alzheimer's disease. It aims to see if these treatments can help keep your brain healthy as you age.
This Phase 3 study looks for blood/brain “biomarkers” linked to aging, memory changes, and early brain degeneration. It may help researchers better identify who is at risk and how biology relates to thinking and memory, using brain scans and thinking tests.
This study identifies people at high risk for Alzheimer's disease before symptoms develop, using genetics and digital tools to track brain health over time. If you qualify, you'll help researchers understand who will develop cognitive decline and potentially enable earlier interventions.
This trial tests a new medicine called LY4006895 in two groups: healthy volunteers and people with early symptomatic Alzheimer's disease. It aims to see how the drug works in the body and if it might help memory and thinking.
This trial tests an experimental drug called HT-4253 to see if it can prevent Alzheimer's disease in people who are at higher genetic risk (carry the APOE4 gene) and have early signs of amyloid buildup in the brain. If you qualify, you would take the drug or a placebo and be monitored over time.
Hear when a new Cerebral Blood Flow trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.